News

Patient enrollment was completed in May 2011, recruiting over 1,400 patients at 180 sites in the US, Europe, Central Eastern Europe and Israel. The primary endpoint of the

YERVOY is a recombinant, human monoclonal antibody that blocks the cytotoxic T- lymphocyte antigen-4 (CTLA-4), a negative regulator of T-cell activation. The US Food and Drug Administration approved

BioVigilant claims its IMD-A 300 and IMD-A 350 systems can detect immediately the presence of bacteria in the drug manufacturing process, in contrast to traditional growth methods. Based

Schiff Nutrition International develops, manufactures, markets and distributes branded and private label vitamins, nutritional supplements and nutrition bars in the US and throughout the world. The agreement allows

TheraMax Migraine Relief nasal spray is specially designed for the migraine headaches. TheraBiogen claims the delivery system will have a direct effect and is absorbed immediately. The new

PharmaNet provides clinical development services to pharmaceutical, biotechnology, generic drug and medical device companies. PharmaNet has been conducting clinical studies for oncology products since 1996 and has an

The study is an open-label, dose-escalating trial which is designed to evaluate the safety and immunogenicity of DPX-0907 in patients with advanced stage breast, ovarian or prostate cancer.

GI-4000 and GI-6207 vaccines are used to target mutated versions of the Ras oncoprotein and CEA expressing tumors respectively. In the first study, GI-4000, a series of Tarmogen

The patent recognizes the company’s intellectual property rights to the composition of matter and methods of use for setrobuvir and related compounds. Setrobuvir, which has received fast track